Belle Mead, NJ, United States of America

Richard Scott Pottorf

This inventor holds 3 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignees: Astrazeneca Ab, Corridor Pharmaceuticals, Inc., University of Pennsylvania. Active years: 2014-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard Scott Pottorf. Retrieved from https://idiyas.com/inventor/richard-scott-pottorf

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 (Patent Applications = 3)

% Patents Active = 33.3

CIPO Patents = 2

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 5.6

ph-index = 2

Forward Citations = 24(Granted Patents)

Company Filing History:

Corridor Pharmaceuticals, Inc.

patent

1 out of 2,659

University of Pennsylvania

patents

where one patent can have more than one assignee

Years Active: 2014-2018

Loading Chart...

3 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10118936 - Arginase inhibitors and methods of use (2018-11-06),

2. 9447122 - Arginase inhibitors and methods of use thereof (2016-09-20),

3. 8894970 - Arginase inhibitors and methods of use thereof (2014-11-25),

Title: The Innovations of Richard Scott Pottorf

Introduction

Richard Scott Pottorf is an accomplished inventor based in Belle Mead, NJ (US). He holds three patents, showcasing his contributions to the field of pharmaceutical sciences. His work primarily focuses on arginase inhibitors, which have significant implications for treating various medical conditions.

Latest Patents

Pottorf's latest patents include innovative compounds aimed at inhibiting arginase activity. One of his notable inventions is directed to arginase inhibitor compounds of specific formulas, along with their pharmaceutically acceptable salts. These compounds are designed for the treatment and diagnosis of conditions characterized by upregulation of arginase or abnormally high arginase activity. Another patent involves methods of treating or diagnosing conditions associated with high arginase activity or low nitric oxide levels in mammals, emphasizing the therapeutic potential of his discoveries.

Career Highlights

Throughout his career, Pottorf has worked with prominent companies in the pharmaceutical industry, including AstraZeneca and Corridor Pharmaceuticals, Inc. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in medical treatments.

Collaborations

Pottorf has collaborated with notable professionals in his field, including Bruce Edward Tomczuk and Gary Olson. These partnerships have likely enhanced his research and development efforts, leading to successful patent applications.

Conclusion

Richard Scott Pottorf's work in developing arginase inhibitors represents a significant advancement in medical science. His patents reflect his dedication to innovation and improving healthcare outcomes.

Profile summary based on public USPTO records.